{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T15:27:45Z","timestamp":1778426865100,"version":"3.51.4"},"reference-count":51,"publisher":"Japanese Society for Lymphoreticular Tissue Research","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCEH","J Clin Exp Hematopathol"],"published-print":{"date-parts":[[2023]]},"DOI":"10.3960\/jslrt.22039","type":"journal-article","created":{"date-parts":[[2023,6,27]],"date-time":"2023-06-27T22:12:49Z","timestamp":1687903969000},"page":"73-82","source":"Crossref","is-referenced-by-count":4,"title":["The clinical impact of the ratio of C-reactive protein to albumin                    (CAR) in patients with acute- and lymphoma-type adult T-cell leukemia-lymphoma                    (ATL)"],"prefix":"10.3960","volume":"63","author":[{"given":"Noriaki","family":"Kawano","sequence":"first","affiliation":[{"name":"Department of Internal Medicine\/Hematology,                            Miyazaki Prefectural Miyazaki Hospital, Miyazaki, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidemi","family":"Shimonodan","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Miyazaki                            Prefectural Miyazaki Hospital, Miyazaki, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuri","family":"Nagahiro","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Jozan Hospital,                            Kumamoto, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuro","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine\/Hematology,                            Miyazaki Prefectural Miyazaki Hospital, Miyazaki, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuro","family":"Kuriyama","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine\/Hematology,                            Miyazaki Prefectural Miyazaki Hospital, Miyazaki, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Takigawa","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine\/Hematology,                            Miyazaki Prefectural Miyazaki Hospital, Miyazaki, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taro","family":"Tochigi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine\/Hematology,                            Miyazaki Prefectural Miyazaki Hospital, Miyazaki, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Nakaike","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine\/Hematology,                            Miyazaki Prefectural Miyazaki Hospital, Miyazaki, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeyoshi","family":"Makino","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine\/Hematology,                            Miyazaki Prefectural Miyazaki Hospital, Miyazaki, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyoshi","family":"Yamashita","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine\/Hematology,                            Miyazaki Prefectural Miyazaki Hospital, Miyazaki, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kousuke","family":"Marutsuka","sequence":"additional","affiliation":[{"name":"Department of Pathology, Miyazaki Prefectural                            Miyazaki Hospital, Miyazaki, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidenobu","family":"Ochiai","sequence":"additional","affiliation":[{"name":"Trauma and Critical Care Center, Faculty of                            Medicine, University of Miyazaki, Miyazaki, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuo","family":"Mori","sequence":"additional","affiliation":[{"name":"Department of Medicine and Biosystemic                            Science, Kyushu University Graduate School of Medical Sciences, Fukuoka,                            Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuya","family":"Shimoda","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hematology,                            Department of Internal Medicine, Faculty of Medicine, University of                            Miyazaki, Miyazaki, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kouichi","family":"Ohshima","sequence":"additional","affiliation":[{"name":"Department of Pathology, Kurume University,                            Fukuoka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Mashiba","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine\/Hematology,                            Miyazaki Prefectural Miyazaki Hospital, Miyazaki, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ikuo","family":"Kikuchi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine\/Hematology,                            Miyazaki Prefectural Miyazaki Hospital, Miyazaki, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2349","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Cook                            LB,                                Fuji                            S,                                Hermine                            O                    <i>et al.<\/i> Revised adult T-cell leukemia-lymphoma international                    consensus meeting report. J Clin Oncol. 2019; 37: 677-687.","DOI":"10.1200\/JCO.18.00501"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Katsuya                            H,                                Ishitsuka                            K. Treatment                    advances and prognosis for patients with adult T-cell leukemia-lymphoma. J Clin                    Exp Hematop. 2017; 57: 87-97.","DOI":"10.3960\/jslrt.17008"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Ishitsuka                            K,                                Tamura                            K. Human T-cell                    leukaemia virus type I and adult T-cell leukaemia-lymphoma. Lancet Oncol. 2014;                    15: e517-e526.","DOI":"10.1016\/S1470-2045(14)70202-5"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Uchiyama                            T,                                Yodoi                            J,                                Sagawa                            K,                                Takatsuki                            K,                                Uchino                            H. Adult T-cell                    leukemia: clinical and hematologic features of 16 cases. Blood. 1977; 50:                    481-492.","DOI":"10.1182\/blood.V50.3.481.481"},{"key":"5","unstructured":"5 Ishida                            T,                                Utsunomiya                            A,                                Iida                            S                    <i>et al.<\/i> Clinical significance of CCR4 expression in adult T-cell                    leukemia\/lymphoma: its close association with skin involvement and unfavorable                    outcome. Clin Cancer Res. 2003; 9: 3625-3634."},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Kataoka                            K,                                Nagata                            Y,                                Kitanaka                            A                    <i>et al.<\/i> Integrated molecular analysis of adult T cell                    leukemia\/lymphoma. Nat Genet. 2015; 47: 1304-1315.","DOI":"10.1038\/ng.3415"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Shimoyama                            M. Diagnostic                    criteria and classification of clinical subtypes of adult T-cell                    leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-87). Br J                    Haematol. 1991; 79: 428-437.","DOI":"10.1111\/j.1365-2141.1991.tb08051.x"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Katsuya                            H,                                Yamanaka                            T,                                Ishitsuka                            K                    <i>et al.<\/i> Prognostic index for acute- and lymphoma-type adult                    T-cell leukemia\/lymphoma. J Clin Oncol. 2012; 30: 1635-1640.","DOI":"10.1200\/JCO.2011.38.2101"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Tsukasaki                            K,                                Utsunomiya                            A,                                Fukuda                            H                    <i>et al.<\/i> VCAP-AMP-VECP compared with biweekly CHOP for adult                    T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801. J Clin                    Oncol. 2007; 25: 5458-5464.","DOI":"10.1200\/JCO.2007.11.9958"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Ishitsuka                            K,                                Yurimoto                            S,                                Tsuji                            Y                    <i>et al.<\/i> Safety and effectiveness of mogamulizumab in relapsed or                    refractory adult T\u2010cell leukemia\u2010lymphoma. Eur J Haematol. 2019; 102:                    407-415.","DOI":"10.1111\/ejh.13220"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Utsunomiya                            A. Progress in                    allogeneic hematopoietic cell transplantation in adult T-cell leukemia-lymphoma.                    Front Microbiol. 2019; 10: 2235.","DOI":"10.3389\/fmicb.2019.02235"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Nosaka                            K,                                Iwanaga                            M,                                Imaizumi                            Y                    <i>et al.<\/i> Epidemiological and clinical features of adult T\u2010cell                    leukemia-lymphoma in Japan, 2010-2011: A nationwide survey. Cancer Sci. 2017;                    108: 2478-2486.","DOI":"10.1111\/cas.13398"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Matsunaga                            T,                                Miyata                            H,                                Sugimura                            K                    <i>et al.<\/i> Prognostic significance of C-reactive                    protein-to-prealbumin ratio in patients with esophageal cancer. Yonago Acta Med.                    2019; 63: 8-19.","DOI":"10.33160\/yam.2020.02.002"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Saito                            H,                                Kono                            Y,                                Murakami                            Y                    <i>et al.<\/i> Prognostic significance of the preoperative ratio of                    C-reactive protein to albumin and neutrophil-lymphocyte ratio in gastric cancer                    patients. World J Surg. 2018; 42: 1819-1825.","DOI":"10.1007\/s00268-017-4400-1"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Kano                            H,                                Midorikawa                            Y,                                Song                            P                    <i>et al.<\/i> High C-reactive protein\/albumin ratio associated with                    reduced survival due to advanced stage of intrahepatic cholangiocarcinoma.                    Biosci Trends. 2020; 14: 304-309.","DOI":"10.5582\/bst.2020.03167"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Arima                            K,                                Yamashita                            Y,                                Hashimoto                            D                    <i>et al.<\/i> Clinical usefulness of postoperative C-reactive                    protein\/albumin ratio in pancreatic ductal adenocarcinoma. Am J Surg. 2018; 216:                    111-115.","DOI":"10.1016\/j.amjsurg.2017.08.016"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Tamagawa                            H,                                Aoyama                            T,                                Tamagawa                            A                    <i>et al.<\/i> Influence of the preoperative C-reactive                    protein-to-albumin ratio on survival and recurrence in patients with esophageal                    cancer. Anticancer Res. 2020; 40: 2365-2371.","DOI":"10.21873\/anticanres.14205"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Kudou                            K,                                Saeki                            H,                                Nakashima                            Y                    <i>et al.<\/i> C-reactive protein\/albumin ratio is a poor prognostic                    factor of esophagogastric junction and upper gastric cancer. J Gastroenterol                    Hepatol. 2019; 34: 355-363.","DOI":"10.1111\/jgh.14442"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Miyamoto                            T,                                Fujitani                            M,                                Fukuyama                            H                    <i>et al.<\/i> The C-reactive protein\/albumin ratio is useful for                    predicting short-term survival in cancer and noncancer patients. J Palliat Med.                    2019; 22: 532-537.","DOI":"10.1089\/jpm.2018.0404"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Komura                            N,                                Mabuchi                            S,                                Shimura                            K                    <i>et al.<\/i> Significance of pretreatment C-reactive protein,                    albumin, and C-reactive protein to albumin ratio in predicting poor prognosis in                    epithelial ovarian cancer patients. Nutr Cancer. 2021; 73:                    1357-1364.","DOI":"10.1080\/01635581.2020.1798479"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Ueda                            K,                                Ogasawara                            N,                                Yonekura                            S                    <i>et al.<\/i> The prognostic value of systemic inflammatory markers in                    advanced renal cell carcinoma patients treated with molecular targeted                    therapies. Anticancer Res. 2020; 40: 1739-1745.","DOI":"10.21873\/anticanres.14127"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 Nakao                            Y,                                Yamashita                            YI,                                Arima                            K                    <i>et al.<\/i> Clinical usefulness of perioperative C-reactive                    protein\/albumin ratio in patients with intrahepatic cholangiocarcinoma: A                    Retrospective Single Institutional Study. Anticancer Res. 2019; 39:                    2641-2646.","DOI":"10.21873\/anticanres.13388"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Kuboki                            A,                                Kanaya                            H,                                Nakayama                            T                    <i>et al.<\/i> Prognostic value of C\u2010reactive protein\/albumin ratio for                    patients with hypopharyngeal and laryngeal cancer undergoing invasive surgery                    involving laryngectomy. Head Neck. 2019; 41: 1342-1350.","DOI":"10.1002\/hed.25565"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 Ito                            T,                                Shinkawa                            H,                                Takemura                            S                    <i>et al.<\/i> Impact of the preoperative C-reactive protein to albumin                    ratio on the long-term outcomes of hepatic resection for intrahepatic                    cholangiocarcinoma. Asian Pac J Cancer Prev. 2020; 21:                    2373-2379.","DOI":"10.31557\/APJCP.2020.21.8.2373"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25 Murakawa                            M,                                Yamamoto                            N,                                Kamioka                            Y                    <i>et al.<\/i> Clinical implication of pre-operative C-reactive                    protein-albumin ratio as a prognostic factor of patients with pancreatic ductal                    Adenocarcinoma: A Single-institutional Retrospective Study. In Vivo. 2020; 34:                    347-353.","DOI":"10.21873\/invivo.11780"},{"key":"26","unstructured":"26 Shibutani                            M,                                Maeda                            K,                                Nagahara                            H                    <i>et al.<\/i> Prognostic significance of the preoperative ratio of                    C-reactive protein to albumin in patients with colorectal cancer. Anticancer                    Res. 2016; 36: 995-1001."},{"key":"27","doi-asserted-by":"crossref","unstructured":"27 Otowa                            Y,                                Nakamura                            T,                                Yamamoto                            M                    <i>et al.<\/i> C-reactive protein to albumin ratio is a prognostic                    factor for patients with cStage II\/III esophageal squamous cell cancer. Dis                    Esophagus. 2017; 30: 1-5.","DOI":"10.1093\/dote\/dox107"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28 Kinoshita                            A,                                Onoda                            H,                                Imai                            N                    <i>et al.<\/i> The C-reactive protein\/albumin ratio, a novel                    inflammation-based prognostic score, predicts outcomes in patients with                    hepatocellular carcinoma. Ann Surg Oncol. 2015; 22: 803-810.","DOI":"10.1245\/s10434-014-4048-0"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29 Haruki                            K,                                Shiba                            H,                                Shirai                            Y                    <i>et al.<\/i> The C-reactive protein to albumin ratio predicts                    long-term outcomes in patients with pancreatic cancer after pancreatic                    resection. World J Surg. 2016; 40: 2254-2260.","DOI":"10.1007\/s00268-016-3491-4"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30 Shibutani                            M,                                Maeda                            K,                                Nagahara                            H                    <i>et al.<\/i> The significance of the C-reactive protein to albumin                    ratio as a marker for predicting survival and monitoring chemotherapeutic                    effectiveness in patients with unresectable metastatic colorectal cancer.                    Springerplus. 2016; 5: 1798.","DOI":"10.1186\/s40064-016-3529-y"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31 Haruki                            K,                                Shiba                            H,                                Horiuchi                            T                    <i>et al.<\/i> Impact of the C-reactive protein to albumin ratio on                    long-term outcomes after hepatic resection for colorectal liver metastases. Am J                    Surg. 2017; 214: 752-756.","DOI":"10.1016\/j.amjsurg.2017.02.001"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32 Tsujino                            T,                                Komura                            K,                                Hashimoto                            T                    <i>et al.<\/i> C-reactive protein-albumin ratio as a prognostic factor                    in renal cell carcinoma - A data from multi-institutional study in Japan. Urol                    Oncol. 2019; 37: 812.e1-812.e8.","DOI":"10.1016\/j.urolonc.2019.04.002"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33 Miyazaki                            T,                                Yamasaki                            N,                                Tsuchiya                            T                    <i>et al.<\/i> Ratio of C-reactive protein to albumin is a prognostic                    factor for operable non-small-cell lung cancer in elderly patients. Surg Today.                    2017; 47: 836-843.","DOI":"10.1007\/s00595-016-1448-8"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34 Toiyama                            Y,                                Shimura                            T,                                Yasuda                            H                    <i>et al.<\/i> Clinical burden of C-reactive protein\/albumin ratio                    before curative surgery for patients with gastric cancer. Anticancer Res. 2016;                    36: 6491-6498.","DOI":"10.21873\/anticanres.11248"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35 Ishizuka                            M,                                Nagata                            H,                                Takagi                            K                    <i>et al.<\/i> Clinical significance of the C-reactive protein to                    albumin ratio for survival after surgery for colorectal cancer. Ann Surg Oncol.                    2016; 23: 900-907.","DOI":"10.1245\/s10434-015-4948-7"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36 Tominaga                            T,                                Nonaka                            T,                                Sumida                            Y                    <i>et al.<\/i> The C-reactive protein to albumin ratio as a predictor                    of severe side effects of adjuvant chemotherapy in stage III colorectal cancer                    patients. PLoS One. 2016; 11:                    e0167967.","DOI":"10.1371\/journal.pone.0167967"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37 Shimizu                            T,                                Ishizuka                            M,                                Suzuki                            T                    <i>et al.<\/i> The value of the C-reactive protein-to-albumin ratio is                    useful for predicting survival of patients with Child-Pugh class A undergoing                    liver resection for hepatocellular carcinoma. World J Surg. 2018; 42:                    2218-2226.","DOI":"10.1007\/s00268-017-4446-0"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38 Fujiwara                            Y,                                Haruki                            K,                                Shiba                            H                    <i>et al.<\/i> The comparison of inflammation-based prognostic scores                    in patients with extrahepatic bile duct cancer after pancreaticoduodenectomy. J                    Surg Res. 2019; 238: 102-112.","DOI":"10.1016\/j.jss.2019.01.033"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39 Xu                            HJ,                                Ma                            Y,                                Deng                            F                    <i>et al.<\/i> The prognostic value of C-reactive protein\/albumin ratio                    in human malignancies: an updated meta-analysis. OncoTargets Ther. 2017; 10:                    3059-3070.","DOI":"10.2147\/OTT.S137002"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40 Cui                            X,                                Jia                            Z,                                Chen                            D,                                Xu                            C,                                Yang                            P. The                    prognostic value of the C-reactive protein to albumin ratio in cancer: an                    updated meta-analysis. Medicine (Baltimore). 2020; 99:                        e19165.","DOI":"10.1097\/MD.0000000000019165"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41 Jung                            J,                                Lee                            H,                                Heo                            JY                    <i>et al.<\/i> High level of pre-treatment C-reactive protein to                    albumin ratio predicts inferior prognosis in diffuse large B-cell lymphoma. Sci                    Rep. 2021; 11: 2674.","DOI":"10.1038\/s41598-021-82087-6"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42 Kawano                            N,                                Yoshida                            S,                                Kuriyama                            T                    <i>et al.<\/i> Clinical features and treatment outcomes of 81 patients                    with aggressive type adult T-cell leukemia-lymphoma at a single institution over                    a 7-year period (2006-2012). Intern Med. 2015; 54: 1489-1498.","DOI":"10.2169\/internalmedicine.54.1953"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43 Nagafuji                            K,                                Miyamoto                            T,                                Eto                            T                    <i>et al.<\/i> Monitoring of minimal residual disease (MRD) is useful                    to predict prognosis of adult patients with Ph-negative ALL: results of a                    prospective study (ALL MRD2002 Study). J Hematol Oncol. 2013; 6:                    14.","DOI":"10.1186\/1756-8722-6-14"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44 Kawano                            N,                                Yoshida                            N,                                Kawano                            S                    <i>et al.<\/i> Clinical features, pathological features, and treatment                    outcomes of 22 patients with aggressive adult T-cell leukemia-lymphoma treated                    with a humanized CCR4 antibody (mogamulizumab) at a single institution during a                    6-year period (2012-2018). Intern Med. 2019; 58: 2159-2166.","DOI":"10.2169\/internalmedicine.2513-18"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45 Yamamura                            M,                                Yamada                            Y,                                Momita                            S,                                Kamihira                            S,                                Tomonaga                            M. Circulating                    interleukin\u20106 levels are elevated in adult T\u2010cell leukaemia\/lymphoma patients                    and correlate with adverse clinical features and survival. Br J Haematol. 1998;                    100: 129-134.","DOI":"10.1046\/j.1365-2141.1998.00538.x"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46 Fuji                            S,                                Yamaguchi                            T,                                Inoue                            Y                    <i>et al.<\/i> Development of a modified prognostic index for patients                    with aggressive adult T-cell leukemia-lymphoma aged 70 years or younger:                    possible risk-adapted management strategies including allogeneic                    transplantation. Haematologica. 2017; 102: 1258-1265.","DOI":"10.3324\/haematol.2017.164996"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47 Kawano                            N,                                Nagahiro                            Y,                                Yoshida                            S                    <i>et al.<\/i> Clinical features and treatment outcomes of                    opportunistic infections among human T-lymphotrophic virus type 1 (HTLV-1)                    carriers and patients with adult T-cell leukemia-lymphoma (ATL) at a single                    institution from 2006 to 2016. J Clin Exp Hematop. 2019; 59:                    156-167.","DOI":"10.3960\/jslrt.18032"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48 Kamihira                            S,                                Atogami                            S,                                Sohda                            H                    <i>et al.<\/i> Significance of soluble interleukin-2 receptor levels                    for evaluation of the progression of adult T-cell leukemia. Cancer. 1994; 73:                    2753-2758.","DOI":"10.1002\/1097-0142(19940601)73:11<2753::AID-CNCR2820731117>3.0.CO;2-X"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49 Shigematsu                            A,                                Kobayashi                            N,                                Yasui                            H                    <i>et al.<\/i> High level of serum soluble interleukin-2 receptor at                    transplantation predicts poor outcome of allogeneic stem cell transplantation                    for adult T cell leukemia. Biol Blood Marrow Transplant. 2014; 20:                    801-805.","DOI":"10.1016\/j.bbmt.2014.02.014"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50 Kogure                            Y,                                Kameda                            T,                                Koya                            J                    <i>et al.<\/i> Whole-genome landscape of adult T-cell                    leukemia\/lymphoma. Blood. 2022; 139: 967-982.","DOI":"10.1182\/blood.2021013568"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51 Guerrero                            CLH,                                Yamashita                            Y,                                Miyara                            M                    <i>et al.<\/i> Proteomic profiling of HTLV-1 carriers and ATL patients                    reveals sTNFR2 as a novel diagnostic biomarker for acute ATL. Blood Adv. 2020;                    4: 1062-1071.","DOI":"10.1182\/bloodadvances.2019001429"}],"container-title":["Journal of Clinical and Experimental Hematopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/63\/2\/63_22039\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T05:11:32Z","timestamp":1688188292000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/63\/2\/63_22039\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":51,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.3960\/jslrt.22039","relation":{},"ISSN":["1346-4280","1880-9952"],"issn-type":[{"value":"1346-4280","type":"print"},{"value":"1880-9952","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023]]},"article-number":"22039"}}